The Online Investor
OLI Premium
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com

Slideshow Private Placements

By The Online Investor Staff, updated Wed., May. 1, 6:16 AM

Slide #12. DelMar Pharmaceuticals, Inc. Private Placement

Company: DelMar Pharmaceuticals, Inc. (DMPI)
$Amount: $1,500,000 (USD)
Closed on: 2/1/2013
Private Placement Details: DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") today announced the second closing in a private placement consisting of approximately 1.9 million units of its securities to qualified accredited investors, for gross proceeds of approximately $1.5 million. The total amount raised in the private placement is $6.9 million.

DelMar Pharmaceuticals is a clinical stage, biopharmaceutical company. Co. is developing VAL-083, a DNA-targeting agent, for the treatment of drug-resistant solid tumors such as glioblastoma multiforme (GBM) and other solid tumors, including ovarian cancer and non-small cell lung cancer. Co. is also conducting open-label, biomarker driven studies in methyl guanine methyltransferase-unmethylated GBM. In addition to its clinical development activities in the United States, Co. has provided Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. certain commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia and lung cancer. DelMar Pharmaceuticals is a clinical stage, biopharmaceutical company. Co. is developing VAL-083, a DNA-targeting agent, for the treatment of drug-resistant solid tumors such as glioblastoma multiforme (GBM) and other solid tumors, including ovarian cancer and non-small cell lung cancer. Co. is also conducting open-label, biomarker driven studies in methyl guanine methyltransferase-unmethylated GBM. In addition to its clinical development activities in the United States, Co. has provided Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. certain commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia and lung cancer.
Open the DMPI Page at The Online Investor »

Company Name:  Kintara Therapeutics Inc
Website:  www.delmarpharma.com
Sector:  Drugs & Pharmaceuticals
 

Open the DMPI Page at The Online Investor (in a new window) »

May 1, 2024    6:16 AM Eastern
Quotes delayed 20 minutes

Email EnvelopeFree DMPI Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Private Placements | www.TheOnlineInvestor.com | Copyright © 1998 - 2024, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.